Serapha takes reverse merger route to Nasdaq with $230M and gene editor from China

The combined business entity with Boundless Bio, which will carry Serapha Bio’s name and fold in Boundless Bio, will focus on the development of a gene editor for alpha-1 antitrypsin deficiency.